Evidence map›Paper›PMID 33414171›Full record

ArticleCancer research2021

CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.

Husheng Ding, Nicole D Vincelette, Cordelia D McGehee, Mira A Kohorst, Brian D Koh, Annapoorna Venkatachalam, X Wei Meng, Paula A Schneider, Karen S Flatten, Kevin L Peterson and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. KIF11 serves as a cell cycle mediator in childhood acute lymphoblastic leukemia.Journal of cancer research and clinical oncology · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Husheng Ding *Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. Kaufmann.Scott@Mayo.edu Ding.Husheng@Mayo.edu.
Nicole D Vincelette *Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Cordelia D McGehee *Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Mira A KohorstDepartment of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Brian D KohDivision of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Annapoorna VenkatachalamDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
X Wei MengDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Paula A SchneiderDivision of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Karen S FlattenDivision of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Kevin L PetersonDivision of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Cristina CorreiaDivision of Oncology Research, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9464-7555
Sun-Hee LeeDivision of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Mrinal PatnaikDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Jonathan A WebsterSidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland.ORCID 0000-0003-3647-6345
Gabriel GhiaurSidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland.
B Douglas SmithSidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland.ORCID 0000-0002-0903-7390
Judith E KarpSidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland.ORCID 0000-0003-4754-127X
Keith W PratzSidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Larry M KarnitzDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Scott H KaufmannDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. Kaufmann.Scott@Mayo.edu Ding.Husheng@Mayo.edu.ORCID 0000-0002-4900-7145
Mayo Clinic · USSidney Kimmel Cancer Center · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Predoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4M
Regulation of Death Ligand-Induced KillingR01CA172503 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H · 2015 to 2019
$1.9M
Targeting Chk1 in Acute Myeloid LeukemiaR01CA190473 · NCI · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2015 to 2019
$1.8M
Pharmacogenomic regulation of CYP transcription by TSPYL genesR01GM125633 · NIGMS · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2018 to 2021
$1.2M
A Systems Biology Approach to Mechanisms of PARP Inhibitor Resistance in Ovarian CancerF30CA213737 · NCI · MAYO CLINIC ROCHESTER · PI MCGEHEE, CORDELIA · 2017 to 2021
$190k
NCI NIH HHS F30 CA213737NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA172503NCI NIH HHS R01 CA190473NIGMS NIH HHS R01 GM125633NIGMS NIH HHS T32 GM072474
6 · The paper itself

Abstract

Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the same cytotoxic mechanism. Here we observed that CHK1 inhibition induces apoptosis in a subset of acute leukemia cell lines

Indexed as

AnimalsApoptosisCell ProliferationCyclin-Dependent Kinase 2FemaleGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteMiceMice, Inbred NODMice, SCIDPrecursor Cell Lymphoblastic Leukemia-LymphomaPyrazinesPyrazolesTumor Cells, CulturedTumor Necrosis Factor-alphaCDK2 protein, humanCyclin-Dependent Kinase 2prexasertibPyrazinesPyrazolesTNF protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID33414171
PMCPMC8137540
OpenAlexW3118260944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.